New Abbott Test Now Available in Canada to Aid Doctors in Evaluating Potential Heart Attacks
Innovative test may help clinicians reduce time in diagnosing heart attacks and assist in determining risk for those who may have future heart attacks
MONTREAL, Sept. 12, 2013 – Canadians suffer from about 70,000 heart attacks each year, which is approximately one heart attack every seven minutes.[i] Worldwide, an estimated 17 million people die annually of cardiovascular diseases, specifically heart attacks or strokes.[ii] Time is a critical factor in diagnosing and treating people who may be having a potential heart attack. To aid physicians in detecting heart attacks sooner, Abbott is announcing Health Canada approval for the ARCHITECT STAT High Sensitive Troponin-I (hsTnI) Assay.
Diagnosing Potential Heart Attacks
Cardiac troponin, a protein found in the heart muscle, is considered the preferred biomarker used to identify suspected heart attacks, because it can detect injury to the heart.[iii] Abbott's ARCHITECT STAT hsTnI assay can measure very low levels of the protein, which allows doctors to evaluate whether or not patients are having a heart attack within two to four hours after presentation.[iv] This faster evaluation could allow doctors to reduce the time to diagnosis and treatment by several hours when compared to standard troponin tests. For patients who are having a heart attack, the length of time to diagnosis is a crucial factor because heart muscle cells start to die after the heart stops receiving blood, and eventually, almost all the affected parts of the heart could be irreversibly damaged.
"The advantage of high-sensitivity cardiac troponin tests are that they can offer precise measurements at lower concentrations that are indicative of myocardial injury," said Dr. Peter Kavsak Associate Professor, Department of Pathology and Molecular Medicine, McMaster University and Clinical Biochemist and Scientist at Hamilton Health Sciences. "This is important information for patient care as it will provide clinicians with an important tool in evaluating patients presenting with symptoms suggestive of a heart attack."
Importance to Women
Preliminary findings from a study of 1,126 patients presenting with symptoms of a heart attack were announced at the European Society of Cardiology (ESC) Congress 2013. The study, which is being conducted by researchers at the University of Edinburgh, is evaluating Abbott's ARCHITECT STAT High Sensitive Troponin-I (hsTnI), which is now approved and launched in Canada.
Early findings from this study suggest that women have lower peak levels of troponin than men, contributing to the under-diagnosis and therefore under-treatment of heart attacks for women. These results suggest that Abbott's hsTnI test may help doctors improve the diagnosis and prognosis of patients presenting with symptoms of a heart attack, especially for women.[v]
"While Abbott's high sensitive troponin test benefits both men and women with earlier detection of heart attacks, the potential to increase the diagnosis among women is especially important," said John Frels, PhD, divisional vice president, Diagnostics Research, Abbott. "Abbott’s test provides information to doctors to potentially help impact patient care and the way heart attacks are diagnosed."
For more information on this study, which is set to be completed in 2016 with more than 25,000 patients across 10 centers in Scotland, visit here.
The new assay runs on Abbott's fully-automated ARCHITECT family of analyzers and is available in Canada, as well as in CE marked and non-regulated countries, pending country registration.
The ARCHITECT STAT High Sensitive Troponin-I assay is a chemiluminescent microparticle immunoassay (CMIA) for the quantitative determination of cardiac troponin I (cTnI) in human plasma and serum on the ARCHITECT i System with STAT protocol capability. The cTnI values are used as an aid in the diagnosis of myocardial infarction (MI) and to aid in the assessment of 30-day and 90 day prognosis relative to all-cause mortality and major adverse cardiac events (MACE) consisting of myocardial infarction, revascularization, and cardiac death in patients who present with symptoms suggestive of acute coronary syndrome (ACS).
About Abbott Diagnostics
Abbott is a global leader in in vitro diagnostics and offers a broad range of innovative instrument systems and tests for hospitals, reference labs, molecular labs, blood banks, physician offices and clinics. With more than 22,000 customers in more than 100 countries, Abbott's diagnostic products offer customers automation, convenience, bedside testing, cost effectiveness, and flexibility. Abbott has helped transform the practice of medical diagnosis from an art to a science through the company's commitment to improving patient care and lowering costs.
Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 70,000 people.
In Canada, Abbott has approximately 1,500 employees working in manufacturing, distribution and logistics, as well as sales and marketing. Primary locations in Canada are in Montreal, Markham, Mississauga, Brockville, Ottawa, Victoriaville and Edmonton.
Posted: September 2013